Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05849610
Title	Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)
Acronym	GEM-TECTAL
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	PETHEMA Foundation
Indications	multiple myeloma
Therapies	Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Teclistamab Daratumumab + Talquetamab-tgvs
Age Groups:	adult \| senior
Covered Countries	ESP

Filter rows:

Showing 1 to 10 of 10 entries

Facility	City	Zip	Country	Details
Clinica Universidad de Navarra	Pamplona		Spain	Details
Complejo Hospitalario Santiago (CHUS)	Santiago De Compostela		Spain	Details
H. Universitario Marqués de Valdecilla	Santander		Spain	Details
Hospital Clinic i Provincial de Barcelona	Barcelona		Spain	Details
Hospital Doce de Octubre	Madrid	28041	Spain	Details
Hospital Germans Trials i Pujol	Badalona		Spain	Details
Hospital Universitari i Politecnic la Fe	Valencia		Spain	Details
Hospital Universitario de Salamanca	Salamanca		Spain	Details
Hospital Virgen de la Arrixaca	Murcia		Spain	Details
Hospital Vírgen del Rocío	Sevilla		Spain	Details

Showing 1 to 10 of 10 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field